Safety of rivaroxaban in elderly patients

Glavvrač (Chief Medical Officer) Pub Date : 2023-12-22 DOI:10.33920/med-03-2312-08

K. O. Shnaider, A. P. Kondrakhin, M. L. Maksimov, А. А. Novikova

{"title":"Safety of rivaroxaban in elderly patients","authors":"K. O. Shnaider, A. P. Kondrakhin, M. L. Maksimov, А. А. Novikova","doi":"10.33920/med-03-2312-08","DOIUrl":null,"url":null,"abstract":"Diseases associated with blood clotting disorders are one of the most common problems of a modern person and, accordingly, of the attending physician. Since apixaban is the drug of choice for the treatment of thrombosis and prevention of strokes and embolism, the practitioner needs to be aware of the pharmacological properties and safety of apixaban in special groups of patients. This article provides updated information on the safety of apixaban in patients with kidney disease. We identified potentially relevant studies by searching the electronic databases MEDLINE, Scopus, PubMed, Google Scholar, and the Cochrane Database of Systematic Reviews from January 2022 to November 2023 using the terms: apixaban, anticoagulants,thrombosis, stroke, embolism, kidney disease, chronic kidney disease, therapy, safety, efficacy,adverse effects, clinical trials. Then, according to the inclusion and exclusion criteria, as well as by means of independent selection, all the authors of this article selected the sources meeting the criteria and compiled this review. Recent data show high safety of apixaban, supporting its use as a first-line treatment for thrombosis in patients with kidney diseases.","PeriodicalId":406478,"journal":{"name":"Glavvrač (Chief Medical Officer)","volume":"21 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Glavvrač (Chief Medical Officer)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33920/med-03-2312-08","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Diseases associated with blood clotting disorders are one of the most common problems of a modern person and, accordingly, of the attending physician. Since apixaban is the drug of choice for the treatment of thrombosis and prevention of strokes and embolism, the practitioner needs to be aware of the pharmacological properties and safety of apixaban in special groups of patients. This article provides updated information on the safety of apixaban in patients with kidney disease. We identified potentially relevant studies by searching the electronic databases MEDLINE, Scopus, PubMed, Google Scholar, and the Cochrane Database of Systematic Reviews from January 2022 to November 2023 using the terms: apixaban, anticoagulants,thrombosis, stroke, embolism, kidney disease, chronic kidney disease, therapy, safety, efficacy,adverse effects, clinical trials. Then, according to the inclusion and exclusion criteria, as well as by means of independent selection, all the authors of this article selected the sources meeting the criteria and compiled this review. Recent data show high safety of apixaban, supporting its use as a first-line treatment for thrombosis in patients with kidney diseases.

查看原文本刊更多论文

利伐沙班在老年患者中的安全性

与凝血障碍相关的疾病是现代人最常见的问题之一，因此也是主治医生最常见的问题。由于阿哌沙班是治疗血栓、预防中风和栓塞的首选药物，因此医生需要了解阿哌沙班在特殊患者群体中的药理特性和安全性。本文提供了有关阿哌沙班在肾病患者中安全性的最新信息。我们在 2022 年 1 月至 2023 年 11 月期间检索了 MEDLINE、Scopus、PubMed、Google Scholar 和 Cochrane Database of Systematic Reviews 等电子数据库，以阿哌沙班、抗凝药物、血栓形成、中风、栓塞、肾病、慢性肾病、治疗、安全性、疗效、不良反应、临床试验为关键词，确定了潜在的相关研究。然后，本文所有作者根据纳入和排除标准，并通过独立选择的方式，筛选出符合标准的资料来源，汇编成这篇综述。最近的数据显示阿哌沙班的安全性很高，支持将其作为肾病患者血栓形成的一线治疗药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Glavvrač (Chief Medical Officer)

自引率

0.00%

发文量